Brokerages expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.21) and the highest is ($0.09). Conatus Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.7%. The firm is expected to announce its next earnings results on Wednesday, March 6th.
Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $9.70 million. Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%.
CNAT traded down $0.15 during trading on Tuesday, reaching $4.50. 594,900 shares of the company’s stock were exchanged, compared to its average volume of 606,195. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 2.39. Conatus Pharmaceuticals has a fifty-two week low of $3.22 and a fifty-two week high of $7.95. The firm has a market capitalization of $135.57 million, a PE ratio of -7.38 and a beta of 1.99.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNAT. Alambic Investment Management L.P. boosted its position in shares of Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 178,461 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Conatus Pharmaceuticals by 75.7% during the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after purchasing an additional 60,604 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Conatus Pharmaceuticals during the second quarter worth $547,000. Artal Group S.A. bought a new position in shares of Conatus Pharmaceuticals during the third quarter worth $2,900,000. Finally, MYDA Advisors LLC bought a new position in shares of Conatus Pharmaceuticals during the second quarter worth $154,000. 31.93% of the stock is owned by hedge funds and other institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.